Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 8 recruiting now full pipeline small index

Bronchiectasis: full-pipeline trial registry

8 of 14 indexed Bronchiectasis trials are currently recruiting.

Corpus placement: #1,230 of 28,707 conditions by registered trial count.

14 US clinical trials · 8 currently recruiting · #1,230 of 28,707 conditions by registered trial count

Bronchiectasis: 14 US clinical trials tracked, 8 recruiting.

Bronchiectasis is the subject of 14 registered US clinical trials on ClinicalTrials.gov, 8 of them currently open to new participants. 3 are in Phase 3-4 (later-stage) and 4 in Phase 1-2 (earlier-stage). The most active sponsor is Boehringer Ingelheim, running 3 of these trials.

Enrollment posture brief

Registry condition bronchiectasis

OPEN 8 | RECR 57% | LATE 3 | EARLY 4 | RANK #1230 | SPON 3

Nearest open-share peer: ACL (57% recruiting · 7 trials)

Bronchiectasis (this)57%Acute Respiratory Failure35.7%Adherence, Medication35.7%Acromegaly28.6%Abscess7.1%
Open-enrollment share among volume-matched conditions near Bronchiectasis

Bronchiectasis lists 8 open slots (57% of 14 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Bronchiectasis on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Bronchiectasis is recruiting above its size-band peers.

    8 of 14 indexed trials (57.1%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. One sponsor concentrates Bronchiectasis research.

    Boehringer Ingelheim accounts for 3 of 14 trials (21.4%). 10 distinct sponsors appear on at least one study for this condition label.

  3. Most Bronchiectasis trials plan to enrol fewer than 100 people.

    Median target enrolment is 64 among the 14 trials that report a genuine target (sentinel values excluded). 9 of those (64.3%) plan for fewer than 100 participants.

  4. Bronchiectasis research is mostly interventional.

    11 interventional and 3 observational studies make up this index (78.6% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 11Phase 23Phase 31Phase 42

Open and recent trials

14 total, page 1 of 1

RECRUITING Phase 3 1,755 participants

The AIRTIVITY™ Study: A Study to Find Out Whether BI 1291583 Helps People With Bronchiectasis

Boehringer Ingelheim

NCT06872892

RECRUITING 1,000 participants

Evaluation Of The Lung Microbiome In NTM Bronchiectasis

NYU Langone Health

NCT02779478

RECRUITING 900 participants

Natural History of Bronchiectasis

National Heart, Lung, and Blood Institute (NHLBI)

NCT00943514

RECRUITING NA 800 participants

Acoustic Waveform Respiratory Evaluation

Indiana University

NCT06512064

RECRUITING NA 85 participants

OLE Therapy With BE Patients in Home Care Study

Delve Health

NCT06926881

RECRUITING NA 30 participants

Telehealth and Onsite Maintenance Exercise in Chronic Lung Disease

MGH Institute of Health Professions

NCT06304207

RECRUITING Phase 4 30 participants

Itraconazole Therapy In Bronchiectasis With Airway Mold

Mayo Clinic

NCT07283497

RECRUITING Phase 4 20 participants

Hypertonic Saline in NCFB

University of North Carolina, Chapel Hill

NCT06242795

ACTIVE NOT RECRUITING Phase 2 268 participants

Clairleafᵀᴹ: A Study to Test Long-term Treatment With BI 1291583 in People With Bronchiectasis Who Took Part in a Previous Study With This Medicine

Boehringer Ingelheim

NCT05846230

COMPLETED Phase 2 64 participants

Safety and Tolerability Study of 2 Dose Level of Arikayce™ in Patients With Bronchiectasis and Chronic Infection Due to Pseudomonas Aeruginosa.

Insmed Incorporated

NCT00775138

COMPLETED 35 participants

A Study of Home-based Pulmonary Rehabilitation and Health Coaching to Treat Bronchiectasis

Mayo Clinic

NCT05553119

COMPLETED NA 24 participants

Ex-vivo Perfusion and Ventilation of Lungs Recovered From Non-Heart-Beating Donors to Assess Transplant Suitability

University of North Carolina, Chapel Hill

NCT01615484

COMPLETED Phase 2 22 participants

A Study to Test How Well BI 1291583 is Tolerated by People With Cystic Fibrosis Bronchiectasis (Clairafly™)

Boehringer Ingelheim

NCT05865886

COMPLETED Phase 1 11 participants

A Safety Trial of DAS181 (Fludase®) in Adult Subjects With Well-Controlled Asthma or Bronchiectasis

Ansun Biopharma

NCT01113034

Phase Distribution

PhaseTrial count
Phase 1 1
Phase 2 3
Phase 3 1
Phase 4 2

Named interventions

Most-linked intervention names on Bronchiectasis records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

BI 1291583 Drug
3 trials
Placebo matching BI 1291583 Drug
2 trials
Health coaching calls Behavioral
1 trials
Home Rehabilitation Monitoring System Behavioral
1 trials
Respitose ML006 (DMV-Fonterra) Drug
1 trials
DAS181 dry powder, formulation F02 Drug
1 trials
Placebo to BI 1291583 Drug
1 trials
STEEN Solution™ Device
1 trials

US sites by state

Facility locations filed on Bronchiectasis trials. A trial with sites in several states counts in each.

New York 3 trials
Florida 3 trials
Pennsylvania 2 trials
North Carolina 2 trials
Minnesota 2 trials
Maryland 2 trials
Kansas 2 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Bronchiectasis page

14 registered trials, 8 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Bronchiectasis condition card totals 14 registered trials; most-linked intervention BI 1291583; top US site state New York. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.